Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 9
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Boriani, Giuseppe Cimaglia, Paolo Biffi, Mauro Martignani, Cristian Ziacchi, Matteo Valzania, Cinzia and Diemberger, Igor 2014. Cost-effectiveness of implantable cardioverter-defibrillator in today's world. Indian Heart Journal, Vol. 66, p. S101.


    Pizarro, Gonzalo Fernández-Friera, Leticia Fuster, Valentin Fernández-Jiménez, Rodrigo García-Ruiz, José M. García-Álvarez, Ana Mateos, Alonso Barreiro, María V. Escalera, Noemí Rodriguez, Maite D. de Miguel, Antonio García-Lunar, Inés Parra-Fuertes, Juan J. Sánchez-González, Javier Pardillos, Luis Nieto, Beatriz Jiménez, Adriana Abejón, Raquel Bastante, Teresa Martínez de Vega, Vicente Cabrera, José A. López-Melgar, Beatriz Guzman, Gabriela García-Prieto, Jaime Mirelis, Jesús G. Zamorano, José Luis Albarrán, Agustín Goicolea, Javier Escaned, Javier Pocock, Stuart Iñiguez, Andrés Fernández-Ortiz, Antonio Sánchez-Brunete, Vicente Macaya, Carlos and Ibanez, Borja 2014. Long-Term Benefit of Early Pre-Reperfusion Metoprolol Administration in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, Vol. 63, Issue. 22, p. 2356.


    Freeman, James V. Ullal, Aditya and Turakhia, Mintu P. 2011. Cost-effectiveness of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, Vol. 3, Issue. 3, p. 421.


    Boriani, G. Biffi, M. Martignani, C. Diemberger, I. Valzania, C. Bertini, M. and Branzi, A. 2009. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM, Vol. 102, Issue. 5, p. 349.


    Cappellaro, Giulia Fattore, Giovanni and Torbica, Aleksandra 2009. Funding health technologies in decentralized systems: A comparison between Italy and Spain. Health Policy, Vol. 92, Issue. 2-3, p. 313.


    Noyes, Katia Corona, Ethan Veazie, Peter Dick, Andrew W. Zhao, Hongwei and Moss, Arthur J. 2009. Examination of the Effect of Implantable Cardioverter-Defibrillators on Health-Related Quality of Life. American Journal Cardiovascular Drugs, Vol. 9, Issue. 6, p. 393.


    de Sousa, Marcos R. Morillo, Carlos A. Rabelo, Fábio T. Filho, Antônio M. Nogueira and Ribeiro, Antonio L.P. 2008. Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: A meta-analysis. European Journal of Heart Failure, Vol. 10, Issue. 10, p. 1007.


    Mittal, Suneet 2008. Selecting Patients for an Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, Vol. 51, Issue. 3, p. 297.


    WYSE, D. GEORGE 2007. Economics of Managing Atrial Fibrillation: Broadening the Focus to Include Efficiency. Journal of Cardiovascular Electrophysiology, Vol. 18, Issue. 6, p. 634.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 23, Issue 1
  • January 2007, pp. 63-70

Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation

  • Jackie Bryant (a1), Hakan Brodin (a1), Emma Loveman (a1) and Andrew Clegg (a1)
  • DOI: http://dx.doi.org/10.1017/S0266462307051586
  • Published online: 01 January 2007
Abstract

Objectives: The clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators (ICD) for arrhythmias was assessed.

Methods: A systematic review of the literature of systematic reviews and randomized controlled trials that reported mortality outcomes associated with implantable cardioverter defibrillators compared with antiarrhythmic drug therapy in people at risk of sudden cardiac death due to arrhythmias was undertaken. Economic evaluations were also sought. Inclusion criteria, data extraction, and quality assessment were undertaken by standard methodology. A decision analytic model was constructed using best available evidence to determine cost-effectiveness in a UK setting.

Results: Eight randomized controlled trials, two systematic reviews, and a meta-analysis met the inclusion criteria and were of variable quality. Evidence suggests that ICDs reduce mortality in both secondary and primary prevention, although the magnitude of benefit depends on baseline risk for sudden cardiac death. Incremental cost per quality-adjusted life year ranged from £52,000 ($98,000) to over £200,000 ($379,000), depending on mortality risk and assumptions made.

Conclusions: Evidence suggests that ICDs reduce total mortality but may be cost-effective only in some subgroups of patients at high risk of ventricular arrhythmias. Further research is needed on risk stratification of patients in whom ICDs are most likely to be clinically and cost-effective.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: